AIM: To estimate the cost-benefit of endoscopic screening strategies of esophageal cancer (EC) in high-risk areas of China. METHODS: Markov model-based analyses were conducted to compare the net present values (NPVs) and the benefit-cost ratios (BCRs) of 12 EC endoscopic screening strategies. Strategies varied according to the targeted screening age, screening frequencies, and follow-up intervals. Model parameters were collected from population-based studies in China, published literatures, and surveillance data. RESULTS: Compared with non-screening outcomes, all strategies with hypothetical 100,000 subjects saved life years. Among five dominant strategies determined by the incremental cost-effectiveness analysis, screening once at age 50 years incurred the lowest NPV (international dollar-I$55 million) and BCR (2.52). Screening six times between 40-70 years at a 5-year interval [i.e., six times(40)f-strategy] yielded the highest NPV (I$99 million) and BCR (3.06). Compared with six times(40)f-strategy, screening thrice between 40-70 years at a 10-year interval resulted in relatively lower NPV, but the same BCR. CONCLUSION: EC endoscopic screening is cost-beneficial in high-risk areas of China. Policy-makers should consider the cost-benefit, population acceptance, and local economic status when choosing suitable screening strategies.
AIM: To estimate the cost-benefit of endoscopic screening strategies of esophageal cancer (EC) in high-risk areas of China. METHODS: Markov model-based analyses were conducted to compare the net present values (NPVs) and the benefit-cost ratios (BCRs) of 12 EC endoscopic screening strategies. Strategies varied according to the targeted screening age, screening frequencies, and follow-up intervals. Model parameters were collected from population-based studies in China, published literatures, and surveillance data. RESULTS: Compared with non-screening outcomes, all strategies with hypothetical 100,000 subjects saved life years. Among five dominant strategies determined by the incremental cost-effectiveness analysis, screening once at age 50 years incurred the lowest NPV (international dollar-I$55 million) and BCR (2.52). Screening six times between 40-70 years at a 5-year interval [i.e., six times(40)f-strategy] yielded the highest NPV (I$99 million) and BCR (3.06). Compared with six times(40)f-strategy, screening thrice between 40-70 years at a 10-year interval resulted in relatively lower NPV, but the same BCR. CONCLUSION: EC endoscopic screening is cost-beneficial in high-risk areas of China. Policy-makers should consider the cost-benefit, population acceptance, and local economic status when choosing suitable screening strategies.
Authors: M J Roth; S F Liu; S M Dawsey; B Zhou; C Copeland; G Q Wang; D Solomon; S G Baker; C A Giffen; P R Taylor Journal: Cancer Date: 1997-12-01 Impact factor: 6.860
Authors: M Sant; T Aareleid; F Berrino; M Bielska Lasota; P M Carli; J Faivre; P Grosclaude; G Hédelin; T Matsuda; H Møller; T Möller; A Verdecchia; R Capocaccia; G Gatta; A Micheli; M Santaquilani; P Roazzi; D Lisi Journal: Ann Oncol Date: 2003 Impact factor: 32.976
Authors: S M Dawsey; K J Lewin; G Q Wang; F S Liu; R K Nieberg; Y Yu; J Y Li; W J Blot; B Li; P R Taylor Journal: Cancer Date: 1994-09-15 Impact factor: 6.860
Authors: Don C Codipilly; Yi Qin; Sanford M Dawsey; John Kisiel; Mark Topazian; David Ahlquist; Prasad G Iyer Journal: Gastrointest Endosc Date: 2018-04-27 Impact factor: 9.427
Authors: Benjamin J Di Pardo; Nathan W Bronson; Brian S Diggs; Charles R Thomas; John G Hunter; James P Dolan Journal: World J Surg Date: 2016-02 Impact factor: 3.352
Authors: Yi Qin; Chung W Wu; William R Taylor; Tarek Sawas; Kelli N Burger; Douglas W Mahoney; Zhifu Sun; Tracy C Yab; Graham P Lidgard; Hatim T Allawi; Navtej S Buttar; Thomas C Smyrk; Prasad G Iyer; David A Katzka; David A Ahlquist; John B Kisiel Journal: Clin Cancer Res Date: 2019-09-16 Impact factor: 12.531